This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma (ATO)

This study has been completed.
The V Foundation for Cancer Research
Information provided by (Responsible Party):
Jean Yuh Tang, Stanford University Identifier:
First received: February 12, 2013
Last updated: October 31, 2016
Last verified: October 2016
This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing

Condition Intervention
Basal Cell Carcinoma of the Skin Recurrent Skin Cancer Drug: arsenic trioxide

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by Jean Yuh Tang, Stanford University:

Primary Outcome Measures:
  • Percent Change in Biomarker (GLI2 Protein) Levels [ Time Frame: baseline to day 33 ]

Secondary Outcome Measures:
  • Patients With Stable Disease Post Treatment [ Time Frame: After 3 cycles of treatment (approx. 61 days) ]
    Number of patients with stable disease post treatment by RECIST criteria

  • Patients With Progressive Disease Post Treatment by RECIST Criteria [ Time Frame: After 3 treatment cycles (approx. 61 days) ]
    Patients with a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

  • Incidence of Grade 3/4 Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 [ Time Frame: Baseline to cycle 3 ]

Enrollment: 5
Study Start Date: April 2013
Study Completion Date: November 2015
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (arsenic trioxide)
Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: arsenic trioxide
Given IV
Other Names:
  • Arsenic (III) Oxide
  • Arsenic Sesquioxide
  • Arsenous Acid Anhydride
  • AS2O3
  • Trisenox

Detailed Description:


I. To determine whether administration of arsenic trioxide (ATO) to patients with basal cell carcinoma is associated with a reduction in Gli messenger ribonucleic acid (mRNA) and protein levels in tumor biopsy samples, when compared to baseline levels.


I. To determine whether there is evidence of tumor size reduction of ATO against basal cell carcinoma in humans.


Patients receive arsenic trioxide intravenously (IV) over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with basal cell carcinoma (BCC)
  • Patients ineligible for curative locoregional treatment and have either progressed on, did not tolerate, unwilling to try or ineligible for investigational smoothened antagonist such as vismodegib (GDC 0449), XL 139 (BMS 833923), IPI- 926, LDE225 and PF-04449913
  • Life expectancy estimate > 3 months
  • Performance status Eastern Cooperative Oncology Group (ECOG) 0-2
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Total bilirubin within normal institutional limits
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
  • Creatinine within normal institutional limits
  • Corrected QT interval (QTC) by 12 lead electrocardiogram (EKG) < 450 msecs
  • Serum potassium within normal limits
  • Magnesium within normal limits
  • Calcium within normal limits
  • Include the following: ability to understand and the willingness to sign a written informed consent document
  • Patients must have evaluable tumor and be potentially eligible for pre and post ATO tumor biopsy

Exclusion Criteria:

  • Concurrent use of other Investigational agents is prohibited
  • Patients with cardiac arrhythmias are excluded
  • Patients receiving potassium wasting diuretics or amphotericin, while not excluded, must be noted to have theoretically increased arrhythmia risks with ATO
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, recurrent seizure history or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women and breastfeeding women are excluded from this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01791894

United States, California
Stanford University
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
The V Foundation for Cancer Research
Principal Investigator: Jean Tang Stanford University
  More Information

Responsible Party: Jean Yuh Tang, Associate Professor of Dermatology, Stanford University Identifier: NCT01791894     History of Changes
Other Study ID Numbers: SKIN0015
Study First Received: February 12, 2013
Results First Received: April 27, 2016
Last Updated: October 31, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Results will be submitted to scientific journal for publication and shared at scientific meetings

Additional relevant MeSH terms:
Carcinoma, Basal Cell
Skin Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Neoplasms by Site
Skin Diseases
Arsenic trioxide
Antineoplastic Agents processed this record on September 20, 2017